| Not Yet Recruiting | Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS NCT05602142 | Johns Hopkins University | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients NCT06513546 | PLL TX AUSTRALIA PTY LTD | Phase 1 / Phase 2 |
| Not Yet Recruiting | Digital Speech Markers for Monitoring ALS in Spanish Speakers NCT07341334 | Nova Southeastern University | — |
| Recruiting | Functional Outcomes and Control Using Synchron BCI - Canada NCT07446114 | Synchron, Inc. | N/A |
| Not Yet Recruiting | Healey ALS MyMatch Common Screening Protocol NCT07400393 | Massachusetts General Hospital | — |
| Recruiting | Chinese-Specific Speech Imagery Coding Using High-Density ECoG NCT07460037 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Not Yet Recruiting | Kamlanoflast In Amyotrophic Lateral Sclerosis NCT07396818 | Inflammasome Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | Systems Biology of Amyotrophic Lateral Sclerosis (ALS) NCT07007390 | Viome | — |
| Recruiting | At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis NCT07006571 | University of Trieste | N/A |
| Recruiting | Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) NCT07193953 | Sunnybrook Health Sciences Centre | Phase 1 |
| Recruiting | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis NCT06665165 | Amylyx Pharmaceuticals Inc. | Phase 1 |
| Terminated | RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial NCT06658977 | Macquarie University, Australia | Phase 3 |
| Recruiting | Multicenter ALS Imaging Study NCT06735014 | University of Minnesota | — |
| Recruiting | Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01) NCT06511934 | Leigh R. Hochberg, MD, PhD. | N/A |
| Not Yet Recruiting | Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients NCT05423678 | Power Life Sciences Inc. | — |
| Recruiting | Using the EHR to Advance Genomic Medicine Across a Diverse Health System NCT06377033 | University of Pennsylvania | N/A |
| Recruiting | A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients NCT06453668 | ITB-Med LLC | Phase 1 |
| Recruiting | Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic L NCT06765564 | Shanghai East Hospital | N/A |
| Recruiting | Initiation of Noninvasive Ventilation in ALS Patients With Chronic Respiratory Insufficiency NCT06286917 | Tampere University | N/A |
| Recruiting | Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omic NCT06595212 | Azienda Ospedaliero-Universitaria di Modena | — |
| Recruiting | Emotion Processing Among Patients With ALS NCT06566651 | University of Aarhus | — |
| Unknown | Customized Masks in Non-Invasive Mechanical Ventilation NCT06215391 | Hospital Universitario 12 de Octubre | N/A |
| Recruiting | Combined Respiratory Training in Persons With ALS NCT05913882 | Nova Southeastern University | N/A |
| Completed | Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis NCT05889572 | MaaT Pharma | Phase 1 |
| Terminated | Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation NCT05621213 | AGIR à Dom | N/A |
| Terminated | Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis NCT05683860 | Wave Life Sciences Ltd. | Phase 1 / Phase 2 |
| Completed | Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) NCT05508074 | InFlectis BioScience | Phase 2 |
| Recruiting | NYSCF Scientific Discovery Biobank NCT06203106 | New York Stem Cell Foundation Research Institute | — |
| Completed | Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects NCT05568615 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Factors Associated With Success of NIPPV in ALS Patients NCT05581771 | Seoul National University Bundang Hospital | — |
| Active Not Recruiting | Adenosine 2A Receptor Antagonism and AIH in ALS NCT05377424 | University of Florida | Phase 1 / Phase 2 |
| Completed | A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension NCT05357950 | NeuroSense Therapeutics Ltd. | Phase 2 |
| Terminated | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS NCT05151471 | Tanabe Pharma America, Inc. | Phase 3 |
| Completed | Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral S NCT05163886 | OrphAI Therapeutics | Phase 2 |
| Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266 | Sanguine Biosciences | — |
| Unknown | NF-κB Inhibition in Amyotrophic Lateral Sclerosis NCT05031351 | Sunnybrook Health Sciences Centre | Phase 2 |
| Completed | National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chron NCT06005506 | Institute of Biomedical Technologies-National Research Council, Italy | N/A |
| Active Not Recruiting | Digital Tools for Assessment of Motor Functions and Falls in ALS NCT05271435 | Milton S. Hershey Medical Center | — |
| Terminated | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic L NCT04948645 | AbbVie | Phase 1 |
| Recruiting | PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease NCT04396873 | National Institute of Mental Health (NIMH) | Phase 1 |
| Unknown | Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS NCT04987671 | Amylyx Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Completed | Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients NCT05287958 | Beth Israel Deaconess Medical Center | — |
| Terminated | Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dem NCT04931862 | Wave Life Sciences Ltd. | Phase 1 / Phase 2 |
| Terminated | Multimodal Imaging Outcome Measures for ALS (Image ALS) NCT04490096 | University of Pennsylvania | Phase 1 |
| Terminated | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS NCT04569084 | Tanabe Pharma America, Inc. | Phase 3 |
| Unknown | Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care NCT04138095 | Riverview Health Centre | N/A |
| Completed | Remote Pulmonary Function Testing and Nurse Coaching in ALS NCT04490148 | Milton S. Hershey Medical Center | N/A |
| Terminated | An Efficacy and Safety Study of Ravulizumab in ALS Participants NCT04248465 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | Trial of Oxaloacetate in ALS NCT04204889 | Omar Jawdat | Phase 1 |
| Withdrawn | A Study to Explore the Role of Gut Flora in ALS NCT04150809 | ProgenaBiome | — |
| Completed | Respiratory Muscle Training (RMT) in ALS NCT04224961 | Duke University | N/A |
| Completed | Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS NCT04165850 | NeuroSense Therapeutics Ltd. | Phase 2 |
| Completed | Safety Study of Oral Edaravone Administered in Subjects With ALS NCT04165824 | Tanabe Pharma America, Inc. | Phase 3 |
| Unknown | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) NCT04259255 | Tanabe Pharma America, Inc. | — |
| Terminated | Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products NCT03886753 | Children's Hospital of Philadelphia | — |
| Completed | Speech Analysis in ALS Patients NCT03868345 | Barrow Neurological Institute | — |
| Recruiting | ECoG BMI for Motor and Speech Control NCT03698149 | Karunesh Ganguly | N/A |
| Recruiting | Amyotrophic Lateral Sclerosis (ALS) Families Project NCT03865420 | Columbia University | — |
| Terminated | rTMS in Treatment of Spasticity NCT04054141 | Hospital for Special Surgery, New York | N/A |
| Completed | A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) NCT03506425 | Richard Bedlack, M.D., Ph.D. | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis NCT03472950 | University of Kansas Medical Center | Phase 2 |
| Completed | Open Label Extension Study of AMX0035 in Patients With ALS NCT03488524 | Amylyx Pharmaceuticals Inc. | Phase 2 |
| Withdrawn | Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis NCT03457753 | Aquestive Therapeutics | Phase 2 |
| Completed | Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS NCT03520517 | Biohaven Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS NCT03373981 | Hospital for Special Surgery, New York | N/A |
| Completed | Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot) NCT03214224 | Milton S. Hershey Medical Center | N/A |
| Unknown | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) NCT03272503 | University of Calgary | Phase 2 |
| Active Not Recruiting | Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) NCT03268603 | Mayo Clinic | Phase 2 |
| Completed | A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS NCT03324399 | Avera McKennan Hospital & University Health Center | N/A |
| Completed | Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS) NCT03019419 | Tokyo Medical University | Phase 2 |
| Completed | Deep Phenotyping in Patients With ALS NCT02819765 | Barrow Neurological Institute | — |
| Completed | Effect of MD1003 in Amyotrophic Lateral Sclerosis NCT03114215 | MedDay Pharmaceuticals SA | Phase 2 |
| Completed | Genomic Translation for Amyotrophic Lateral Sclerosis Care NCT02795897 | Columbia University | — |
| Completed | T Cell Phenotypes in Amyotropic Lateral Sclerosis (ALS), Influence of Vitamin D NCT02756104 | University Hospital, Montpellier | N/A |
| Recruiting | Neurologic Stem Cell Treatment Study NCT02795052 | MD Stem Cells | N/A |
| Completed | Safety of Caprylic Triglycerides in ALS: A Pilot Study NCT02716662 | Weill Medical College of Cornell University | N/A |
| Completed | Spinal Interneuron Excitability in ALS NCT02429492 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Completed | A Trial of Tocilizumab in ALS Subjects NCT02469896 | Barrow Neurological Institute | Phase 2 |
| Unknown | Assessment of Voluntary and Reflex Cough in Patients With ALS NCT02495571 | IRCCS San Camillo, Venezia, Italy | N/A |
| Completed | A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) NCT02525471 | Sabrina Paganoni, M.D. | Phase 1 |
| Completed | Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients NCT02457715 | Duke University | — |
| Recruiting | ALS/MND Natural History Study Data Repository NCT05966038 | Massachusetts General Hospital | — |
| Completed | MRI Biomarkers in ALS NCT02405182 | University of Alberta | — |
| Completed | Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis NCT02228915 | University of North Carolina, Chapel Hill | — |
| Terminated | Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis NCT01992029 | University Hospital, Bordeaux | — |
| Completed | Neuromuscular Ultrasound in ALS NCT01785550 | Duke University | — |
| Completed | Evaluation of Metabolomic Analysis in Early Diagnosis of ALS NCT01962311 | University Hospital, Tours | N/A |
| Completed | Differential Study of Muscle Transcriptome NCT01984957 | Assistance Publique - Hôpitaux de Paris | N/A |
| Withdrawn | Coping Effectiveness Training for ALS NCT01583205 | Research Foundation for Mental Hygiene, Inc. | N/A |
| Terminated | Biological Sample Collection for Research and Biobanking NCT04270604 | New York Stem Cell Foundation Research Institute | — |
| Completed | A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers NCT01495390 | Massachusetts General Hospital | — |
| Completed | ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis NCT01393444 | University of Pittsburgh | N/A |
| Completed | Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Scleros NCT01363401 | Corestemchemon, Inc. | Phase 1 / Phase 2 |
| Completed | Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis NCT01124292 | Georgia Institute of Technology | Phase 1 |
| Completed | Optimizing NIPPV Use for Patients With ALS NCT01035476 | University of Pittsburgh | N/A |
| Recruiting | Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis NCT03366506 | Hadassah Medical Organization | — |
| Completed | Talampanel for Amyotrophic Lateral Sclerosis (ALS) NCT00696332 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS) NCT00809224 | University of Michigan | — |
| Completed | Clinical Trial Ceftriaxone in Subjects With ALS NCT00349622 | Massachusetts General Hospital | Phase 3 |
| Completed | Phase II Study Using Thalidomide for the Treatment of ALS NCT00140452 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | Exposure to Neurotoxins as Risk Factors for ALS NCT00340301 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank NCT00076154 | US Department of Veterans Affairs | — |
| Completed | Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis NCT00339976 | National Institute of Environmental Health Sciences (NIEHS) | — |
| No Longer Available | Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS) NCT03537807 | Biohaven Pharmaceuticals, Inc. | — |
| Available | Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS NCT06743776 | Mayo Clinic | — |
| Temporarily Not Available | Intermediate Expanded Access Protocol CNMAu8.EAP04 NCT06408727 | Clene Nanomedicine | — |